These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8581074)

  • 1. Liver disturbances in obesity and diabetes mellitus.
    Van Steenbergen W; Lanckmans S
    Int J Obes Relat Metab Disord; 1995 Sep; 19 Suppl 3():S27-36. PubMed ID: 8581074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatopathy of Mauriac syndrome: a retrospective review from a tertiary liver centre.
    Fitzpatrick E; Cotoi C; Quaglia A; Sakellariou S; Ford-Adams ME; Hadzic N
    Arch Dis Child; 2014 Apr; 99(4):354-7. PubMed ID: 24412980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metabolic diseases and fatty liver].
    Beringer A
    Z Gesamte Inn Med; 1977 May; 32(10):150-2. PubMed ID: 906584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of eicosapentaenoic acid in fatty liver of diabetic subjects.
    Singer P; Honigmann G; Schliack V
    Prostaglandins Med; 1980 Sep; 5(3):183-200. PubMed ID: 6251498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction.
    Van Gaal L
    Verh K Acad Geneeskd Belg; 1989; 51(1):47-80. PubMed ID: 2800685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?
    Yang S; Lin HZ; Hwang J; Chacko VP; Diehl AM
    Cancer Res; 2001 Jul; 61(13):5016-23. PubMed ID: 11431335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation.
    Orellana-Gavaldà JM; Herrero L; Malandrino MI; Pañeda A; Sol Rodríguez-Peña M; Petry H; Asins G; Van Deventer S; Hegardt FG; Serra D
    Hepatology; 2011 Mar; 53(3):821-32. PubMed ID: 21319201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
    Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus.
    Falchuk KR; Fiske SC; Haggitt RC; Federman M; Trey C
    Gastroenterology; 1980 Mar; 78(3):535-41. PubMed ID: 6153166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome.
    Ezquer M; Ezquer F; Ricca M; Allers C; Conget P
    J Hepatol; 2011 Nov; 55(5):1112-20. PubMed ID: 21356258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of streptozotocin-induced and obese diabetic rats.
    Docsa T; Czifrák K; Hüse C; Somsák L; Gergely P
    Mol Med Rep; 2011; 4(3):477-81. PubMed ID: 21468595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fatty acid composition of triglycerides in inflammatory liver diseases in diabetics with and without hyperlipoproteinemia].
    Singer P; Honigmann G; Schliack V
    Z Gesamte Inn Med; 1981 Aug; 36(15):513-9. PubMed ID: 7293284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver pathology in morbidly obese patients with and without diabetes.
    Silverman JF; O'Brien KF; Long S; Leggett N; Khazanie PG; Pories WJ; Norris HT; Caro JF
    Am J Gastroenterol; 1990 Oct; 85(10):1349-55. PubMed ID: 2220728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes.
    Chatila R; West AB
    Medicine (Baltimore); 1996 Nov; 75(6):327-33. PubMed ID: 8982149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease in type 2 diabetes mellitus.
    Cusi K
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):141-9. PubMed ID: 19262374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.